Eli Lilly aims to cut 200 R&D jobs
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
Health Care Businesses
Articles
Lilly CEO encouraged by Trump meeting, concerned about Obamacare
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
Trump spoils pharma chiefs with no more bad news on drug pricing
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
UPDATE: Trump tells drugmakers, including Lilly, their prices are ‘astronomical’
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
Eli Lilly earnings rise sharply but narrowly miss analysts’ expectations
The Indianapolis-based drugmaker got a revenue boost from a host of new medications but also saw sales fall sharply for some older products.
Get ready for a smoking-hot debate over cigarette taxes
Indiana now has one of the lowest cigarette taxes in the nation. It also has one of the highest smoking rates. Some groups want to decrease the latter in part by raising the former.
Former COO of health firm claims discrimination in firing
A former executive at an Indianapolis-based chain of health clinics says he was fired because of his age, race and national origin, and in retaliation because he stood up for one of his female managers.
Lilly shares rise after Alimta cancer drug patent upheld on appeal
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
Lilly exec Azar departs as new CEO makes organizational changes
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
Lilly shares jump after it offers better-than-expected forecast
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
Lilly to sell insulin at 40 percent discount to cash-paying patients
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
Tech entrepreneur Don Brown donating $30M to IU School of Medicine
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
Pharma stocks slide after Trump’s vow to control drug costs
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
Lilly threatens Sanofi’s dominance in insulin with knockoff drug
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
After rough November, some good news for Lilly
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
Lilly competitor to cap price increases as drug costs face more scrutiny
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Lilly to lay off hundreds after failure of Alzheimer’s drug
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Buy, sell or hold after Lilly’s Alzheimer’s flop?
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Failure of Lilly’s Alzheimer’s drug not a big surprise to analysts
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.